References
- Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet. Res. 41(6), 61 (2010).
- Swanepoel R, Coetzer JAW. Rift Valley fever. In: Infectious Diseases of Livestock with Special Reference to Southern Africa (2nd Edition). Coetzer JAW, Thompson GR, Tustin RD et al. (Eds). Oxford University Press, Cape Town, South Africa, 1037–1070 (2004).
- Ikegami T, Makino S. The pathogenesis of Rift Valley fever. Viruses 3(5), 493–519 (2011).
- Ikegami T. Molecular biology and genetic diversity of Rift Valley fever virus. Antiviral Res. 95(3), 293–310 (2012).
- Ikegami T, Makino S. Rift Valley fever vaccines. Vaccine 27(Suppl. 4), D69–D72 (2009).
- Pittman PR, Liu CT, Cannon TL et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 18(1–2), 181–189 (2000).
- Grobbelaar AA, Weyer J, Leman PA, Kemp A, Paweska JT, Swanepoel R. Molecular epidemiology of Rift Valley fever virus. Emerg. Infect. Dis. 17(12), 2270–2276 (2011).
- Caplen H, Peters CJ, Bishop DH. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J. Gen. Virol. 66(10), 2271–2277 (1985).
- Billecocq A, Gauliard N, Le May N, Elliott RM, Flick R, Bouloy M. RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses. Virology 378(2), 377–384 (2008).
- Hunter P, Erasmus BJ, Vorster JH. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J. Vet. Res. 69(1), 95–98 (2002).
- Muller R, Saluzzo JF, Lopez N et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am. J. Trop. Med. Hyg. 53(4), 405–411 (1995).
- Bouloy M, Janzen C, Vialat P et al. Genetic evidence for an interferon-antagonistic function of Rift Valley fever virus nonstructural protein NSs. J. Virol. 75(3), 1371–1377 (2001).
- Dungu B, Louw I, Lubisi A, Hunter P, von Teichman BF, Bouloy M. Evaluation of the efficacy and safety of the Rift Valley fever clone 13 vaccine in sheep. Vaccine 28(29), 4581–4587 (2010).
- Bird BH, Maartens LH, Campbell S et al. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep. J. Virol. 85(24), 12901–12909 (2011).
- Habjan M, Pichlmair A, Elliott RM et al. NSs protein of Rift Valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J. Virol. 83(9), 4365–4375 (2009).
- Moutailler S, Krida G, Madec Y, Bouloy M, Failloux AB. Replication of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, in Aedes and Culex mosquitoes. Vector Borne Zoonotic Dis. 10(7), 681–688 (2010).
- Crabtree MB, Kent Crockett RJ, Bird BH et al. Infection and transmission of Rift Valley fever viruses lacking the NSs and/or NSm genes in mosquitoes: potential role for NSm in mosquito infection. PLoS Negl. Trop. Dis. 6(5), e1639 (2012).
- Dodd KA, Bird BH, Metcalfe MG, Nichol ST, Albariño CG. Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge. J. Virol. 86(8), 4204–4212 (2012).
- Kortekaas J, Oreshkova N, Cobos-Jiménez V, Vloet RP, Potgieter CA, Moormann RJ. Creation of a nonspreading Rift Valley fever virus. J. Virol. 85(23), 12622–12630 (2011).
- Lihoradova O, Kalveram B, Indran SV et al. The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine. J. Virol. 86(14), 7650–7661 (2012).